PSA Response as a Prognostic Factor of Overall Survival in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Real-world Evidence
{{output}}
Background and objective: Prostate-specific antigen (PSA) decline has been proposed as a prognostic marker in metastatic hormone-sensitive prostate cancer (mHSPC). We aimed to evaluate whether a ≥90% PSA decline (PSA 90) predict... ...
